Boston Scientific Looks To Next-Generation DES With Labcoat Deal
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's unique two-drug strategy for drug-eluting stents has propelled the company to a leadership position in the field with, according to some estimates, more than 50% of the DES market. Yet the company is not relying on the current configurations or the current manufacturing approaches for its Taxus (using paclitaxel) and Promus (which employs everolimus) stents to sustain its position on top of this highly competitive product area. With its acquisition this month of Galway, Ireland-based Labcoat Ltd. (terms of which were not disclosed), BSC is laying the groundwork for technology that may well define its next generation of drug-eluting stents
You may also be interested in...
Donald Baim's Death Leaves Gap At Boston Scientific
With the passing of Donald S. Baim, Boston Scientific's front office loses substantial interventional cardiology experience and broad contacts with early-stage device developers
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.